ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2453

Staphylococcus Aureus Carriage Rates Are High in Rheumatoid Arthritis Patients on Biologics

Susan M. Goodman1, Bo Shopsin2, Allina A. Nocon1, Andy O. Miller3, Michael W. Henry3, Sarah E. Grond1, Elianna Kaplowitz1, Thomas P. Sculco4, Linda A. Russell3, Laura T. Donlin5, Mark P. Figgie4 and Peter K. Sculco4, 1Hospital for Special Surgery, New York, NY, 2Medicine and Microbiology, New York University School of Medicine, New York, NY, 3Medicine, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 4Orthopaedic Surgery, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 5Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Bacterial infections, Biologics, Infection, rheumatoid arthritis (RA) and surgery

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with rheumatoid arthritis (RA) have a higher risk of surgical site infection  than patients with osteoarthritis (OA). Disease modifying therapy is widely used by RA patients, and biologic medications may increase Staphylococcus aureus colonization rates.  Because S. aureus colonization likely increases risk of surgical infection, perioperative assessments and therapies to decrease risk of invasive S.aureus infections may be warranted.  The objective of this study was to determine if there was a difference in S. aureus carriage among patients with RA, OA, and RA on biologics (RA+B). 

Methods: An a priori power analysis determined 123 participants per group were needed to detect a relative difference of 20% with 80% power.  After IRB approval, patients were screened; included patients met ACR classification criteria. Patients were approached between April 2017 and May 2018 and performed a nasal swab using the Center for Disease Control’s swabbing protocol; questionnaires pertaining to health status were collected.  Swabs were inoculated onto ChromAgar/ChromID MRSA plates for detection of S. aureus.   Mann-Whitney U and Chi-square tests were used to evaluate baseline differences between groups. Logistic regression evaluated the associations between groups and S. aureus carriage. All statistical analyses were performed using SAS Software version 9.3 (SAS Institute, Cary, NC); statistical significance was defined as p<0.05.

Results: Overall the cohort evaluated had a mean age of 66 (+/-13.7), BMI of 28 (+/-7.0), and were predominantly female (78%) (Table 1). 28% were on antibiotics within three months prior to the swab, 18% were currently on steroids, and 24% had been hospitalized within the last year. We found differences in age (p<0.001), BMI (p<0.001), sex (p<0.001), diabetes (p=0.04), steroid use (p=0.02), antibiotic use (p<0.001), and hospitalizations within the last year (p<0.001). S. aureus carriage was most prevalent in RA+B (37%), followed by RA (24%), and OA (20%). After multivariate adjustment, RA+B was found to have increased odds of S. aureus (OR=1.80, 95% CI 1.00-3.22); p=0.047) compared to RA. Use of glucocorticoids, hospitalization, or diabetes did not increase odds of S. aureus carriage. The OA group had decreased odds of S. aureus compared to the RA group; however this was not statistically significant (p=0.987).

Conclusion: RA patients treated with biologics have an increased prevalence of S. aureus colonization. Since nasal S. aureus carriage may play a role in the pathogenesis of surgical infections, S. aureus decolonization should be considered in RA patients on biologics prior to elective surgery.


Disclosure: S. M. Goodman, Roche, Novartis, 4; B. Shopsin, None; A. A. Nocon, None; A. O. Miller, None; M. W. Henry, None; S. E. Grond, None; E. Kaplowitz, None; T. P. Sculco, Exactech, Inc., 7,Lima Corporate, 5; L. A. Russell, None; L. T. Donlin, None; M. P. Figgie, None; P. K. Sculco, Lima, 5.

To cite this abstract in AMA style:

Goodman SM, Shopsin B, Nocon AA, Miller AO, Henry MW, Grond SE, Kaplowitz E, Sculco TP, Russell LA, Donlin LT, Figgie MP, Sculco PK. Staphylococcus Aureus Carriage Rates Are High in Rheumatoid Arthritis Patients on Biologics [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/staphylococcus-aureus-carriage-rates-are-high-in-rheumatoid-arthritis-patients-on-biologics/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/staphylococcus-aureus-carriage-rates-are-high-in-rheumatoid-arthritis-patients-on-biologics/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology